ORION CORPORATION PRESS RELEASE 8 JANUARY 2026 at 12.00 EET Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in ...

Lung cancer and pleural mesothelioma are often confused, so it’s important to understand the key differences between them, including tumor location and treatments. Lung cancer and pleural mesothelioma ...

In the last few years the health-damaging effects of asbestos have led to an increase in pleural cancers. A new interdisciplinary research laboratory is set to lead to scientific advances in treatment ...

Lung is the leading cancer site in males, comprising 17% of the total new cancer cases and 23% of the total cancer deaths. Cancer survival tends to be poorer in developing countries, most likely ...

Fibulin-3 (FBLN3) was recently presented as a promising novel biomarker for malignant pleural mesothelioma (MPM), warranting independent validation studies. ELISA was used to measure cellular and ...

A brand-new pleural clinic has officially launched at Doncaster Royal Infirmary (DRI), providing faster and more efficient ...

Background: Pleural cancer is a recognised indicator of exposure to asbestos and mesothelioma mortality. Aims: To investigate the distribution of municipal mortality due to this tumour, using the ...

Ethnic difference in chemoradiation-induced esophagitis in unresectable stage III non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This ...

Mesothelioma usually starts in the tissue covering the lung (the pleura). Less often, it can start in tissue in your tummy (peritoneum). You have radiotherapy in a hospital radiotherapy department.